Egetis Therapeutics AB (publ) (STO: EGTX)

Market Cap	1.95B
Revenue (ttm)	67.90M
Net Income (ttm)	-319.30M
Shares Out	359.24M
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,128
Open	5.45
Previous Close	5.43
Day's Range	5.45 - 5.54
52-Week Range	4.04 - 9.30
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 28
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EGTX

Financial Performance

In 2023, Egetis Therapeutics AB's revenue was 57.60 million, an increase of 154.87% compared to the previous year's 22.60 million. Losses were -326.90 million, 68.7% more than in 2022.